Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Could This Stock Be the Next Biotech Buyout?


The biotechnology industry is getting more attention than usual following a buyout offer for Alpine Immune Sciences (NASDAQ: ALPN) from Vertex Pharmaceuticals (NASDAQ: VRTX).

Vertex recently offered Alpine Immune Sciences $65 per share, or about $4.9 billion in cash. On April 9, the day before the announcement, Alpine's stock price closed at about $39 per share.

Government regulators rarely try to prevent big pharmaceutical companies from acquiring clinical-stage biotechs. This means Alpine shareholders will most likely see their investment increase by about 67% when the deal closes, probably in a couple of months.

Continue reading


Source Fool.com

Vertex Pharmaceuticals Inc. Stock

€456.30
1.110%
There is an upward development for Vertex Pharmaceuticals Inc. compared to yesterday, with an increase of €5.05 (1.110%).
With 55 Buy predictions and 2 Sell predictions Vertex Pharmaceuticals Inc. is one of the favorites of our community.
However, we have a potential of -1.38% for Vertex Pharmaceuticals Inc. as the target price of 450 € is below the current price of 456.3 €.
Like: 0
Share

Comments